Assembly Biosciences, Inc. (ASMB) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Assembly Biosciences is a biotechnology company developing therapeutics for serious viral diseases, including recurrent genital herpes, hepatitis B (HBV), hepatitis delta (HDV), and transplant-related herpesviruses. The company operates in a single segment and has no approved products to date. Revenue is derived primarily from a strategic collaboration with Gilead Sciences, Inc.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Collaboration Revenue | $9.6 million | $8.5 million | $19.0 million | $14.3 million |
| Net Loss | $(10.2) million | $(11.2) million | $(19.0) million | $(20.2) million |
| Net Loss Per Share | $(1.33) | $(1.98) | $(2.51) | $(3.64) |
| Operating Expenses | $20.7 million | $20.7 million | $40.1 million | $37.3 million |
| Cash & Marketable Securities | $75.0 million (as of June 30, 2025) | |||
| Accumulated Deficit |
Liquidity: As of June 30, 2025, the company held $24.0 million in cash and cash equivalents and $51.0 million in marketable securities. Net cash used in operating activities for the six months ended June 30, 2025, was $40.2 million.
Material Changes vs. Prior Period
- Revenue Growth: Collaboration revenue increased 13% quarter-over-quarter and 33% year-over-year (YTD). This increase is attributed to higher costs incurred under the Gilead Collaboration Agreement and an increased transaction price following the First Amendment to the agreement in December 2024.
- Expense Management: Total operating expenses remained relatively flat quarter-over-quarter ($20.7 million in both periods). However, YTD expenses increased 8% to $40.1 million, driven by a 121% increase in external program expenses for the ABI-5366 candidate (genital herpes) and the initiation of the ABI-7423 program.
- Interest Income Decline: Interest and other income decreased 39% quarter-over-quarter and 35% YTD due to a smaller investment portfolio balance and lower interest rates.
- Equity Issuance: During the six months ended June 30, 2025, the company sold 161,645 shares under its At-The-Market (ATM) program, raising net proceeds of $1.9 million. No significant equity raises occurred in the same period in 2024.
Outlook, Risks, and Management Commentary
Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. Current cash and marketable securities ($75.0 million) are not expected to fund operations beyond one year from the filing date (into mid-2026). The company plans to mitigate this by seeking additional equity financing and relying on potential future payments from Gilead.
Clinical Progress:
- ABI-5366 & ABI-1179 (Genital Herpes): Both candidates are in Phase 1b studies. Interim data from Phase 1a was positive, supporting progression. Interim Phase 1b data is expected in Fall 2025.
- ABI-6250 (HDV Entry Inhibitor): Phase 1a study is ongoing. Interim data showed a mean half-life of ~4 days, supporting once-daily dosing. Dose-dependent elevations in bile acids were observed, consistent with target engagement.
- ABI-4334 (HBV Capsid Modulator): Topline Phase 1b results (June 2025) showed mean declines in HBV DNA of 2.9 to 3.2 log10 IU/mL. The candidate was well-tolerated.
- ABI-7423 (Transplant Herpesviruses): Nominated as a development candidate in December 2024; currently in regulatory filing-enabling studies.
Risks: Key risks include the inability to secure additional funding, failure of clinical trials, Gilead's decision not to exercise opt-in rights on pipeline programs, and potential regulatory delays due to government staffing changes.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for when current liquidity ($75.0M) will be exhausted and the status of any new financing discussions.
- Gilead Opt-In Triggers: Review the specific clinical milestones required for Gilead to exercise its options on the HPI and NNPI programs, as future revenue depends heavily on these events.
- ABI-6250 Safety Profile: Monitor upcoming data regarding the observed elevations in bile acids and off-target engagement to ensure they do not impact the development plan.
- ATM Program Capacity: Check the remaining capacity under the $75.0 million ATM sales agreement to assess near-term fundraising flexibility.
- Going Concern Mitigation: Scrutinize management's specific plans for raising capital, as the filing explicitly states funding is not assured.